Stockscreener 앱 받기
30.38
0.73%
0.22
시간 외 거래:
30.12
-0.26
-0.86%
전일 마감가:
$30.16
열려 있는:
$30.25
하루 거래량:
567.63K
Relative Volume:
1.51
시가총액:
$831.19M
수익:
$79.95M
순이익/손실:
$-4.60M
주가수익비율:
-170.01
EPS:
-0.1787
순현금흐름:
$10.19M
1주 성능:
+25.75%
1개월 성능:
+21.57%
6개월 성능:
+57.82%
1년 성능:
+79.02%
1일 변동 폭
$30.10
$32.31
1주일 범위
$23.33
$32.31
52주 변동 폭
$13.09
$32.31
Eton Pharmaceuticals Inc Stock (ETON) Company Profile
명칭
Eton Pharmaceuticals Inc
전화
(847) 787-7361
주소
21925 W. FIELD PARKWAY, DEER PARK, IL
Compare ETON vs TAK, ZTS, TEVA, HLN, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ETON
Eton Pharmaceuticals Inc
|
30.38 | 825.17M | 79.95M | -4.60M | 10.19M | -0.1787 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Eton Pharmaceuticals Inc Stock (ETON) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-23 | 재확인 | H.C. Wainwright | Buy |
| 2025-01-10 | 개시 | B. Riley Securities | Buy |
| 2025-01-06 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-04 | 재개 | H.C. Wainwright | Buy |
| 2024-05-06 | 개시 | Craig Hallum | Buy |
| 2021-10-14 | 재개 | B. Riley Securities | Buy |
| 2021-01-04 | 재확인 | H.C. Wainwright | Buy |
| 2019-09-20 | 개시 | B. Riley FBR | Buy |
| 2019-06-10 | 개시 | H.C. Wainwright | Buy |
모두보기
Eton Pharmaceuticals Inc 주식(ETON)의 최신 뉴스
Eton Pharmaceuticals (ETON) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Eton Scales New Highs On Sustained Growth Momentum - RTTNews
Eton Pharmaceuticals (ETON) surges 19.8%: Is this an indication of further gains? - MSN
Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026 - The Manila Times
Eton Pharmaceuticals sets May 14 earnings report, webcast at 4:30 p.m. ET - Stock Titan
Eton Pharmaceuticals (ETON) Surges 19.8%: Is This an Indication of Further Gains? - Yahoo Finance
How The Hemangeol Deal Is Rewriting The Story For Eton Pharmaceuticals (ETON) - Yahoo Finance
Eton Pharmaceuticals Touches New High Amid Relaunch of Hemangeol - Moomoo
Eton Pharmaceuticals (NASDAQ:ETON) Reaches New 12-Month HighTime to Buy? - MarketBeat
Eton Pharmaceuticals (NASDAQ:ETON) Trading 13.3% HigherWhat's Next? - MarketBeat
Eton Pharmaceuticals Relaunches HEMANGEOL With Exclusive Distribution - TipRanks
Eton Pharmaceuticals relaunches Hemangeol with specialty pharmacy By Investing.com - Investing.com Australia
Eton Pharmaceuticals, Inc. (ETON) announced that its product Hemangeol® (propranolol) oral solution has been officially relaunched. - Bitget
Eton Pharmaceuticals relaunches Hemangeol with specialty pharmacy - Investing.com
Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution - The Manila Times
Eton Pharmaceuticals Announces Exclusive Launch of HEMANGEOL Through Anovo Specialty Pharmacy to Enhance Patient Access and Support for Infantile Hemangioma Treatment - Quiver Quantitative
Only FDA-approved infantile hemangioma drug returns with $0 copay - Stock Titan
Does Eton Pharmaceuticals (ETON) have the potential to rally 49.25% as Wall Street analysts expect? - MSN
Eton Pharmaceuticals (ETON) soars 6.7%: Is further upside left in the stock? - MSN
Eton Pharma drops after CFO succession plan - MSN
Recent price trend in Eton Pharmaceuticals (ETON) is your friend, here's why - MSN
Eton Pharmaceuticals Initiates Clinical Study for ET-700 Zinc Acetate Extended-Release Formulation for Wilson Disease - Minichart
Eton Starts Pilot Trial of ET-700 for Wilson Disease - TipRanks
Eton Pharmaceuticals doses first patient in Wilson disease study By Investing.com - Investing.com Australia
Eton Pharmaceuticals doses first patient in Wilson disease study - Investing.com
Eton Pharmaceuticals Announces First Patient Dosed in Pilot Study for ET-700 in Wilson Disease Treatment - Quiver Quantitative
Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700 - The Manila Times
Eton Pharmaceuticals Initiates Clinical Study For Product Candidate ET-700 - marketscreener.com
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Rating of "Hold" by Brokerages - MarketBeat
(ETON) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Eton Pharmaceuticals (ETON) price target increased by 25.56% to 38.42 - MSN
Eton Pharmaceuticals (ETON) 2026 proxy outlines director votes and 2025 CEO pay - Stock Titan
Eton Pharmaceuticals (ETON) Appoints Judith M. Matthews as New CFO - Insider Monkey
10 Best NASDAQ Growth Stocks to Buy and Hold Forever - Insider Monkey
Eton Pharmaceuticals sees its composite rating rise to 97 - MSN
The Escalator: Pfizer, Eton Pharmaceuticals, Steak ‘n Shake and more - Medical Marketing and Media
ETON (Eton Pharmaceuticals Inc.) posts wide Q4 2025 EPS miss, shares edge lower on underwhelming quarterly results.Professional Trade Ideas - Xã Thanh Hà
Eton director exercises options for 32,155 shares | ETON Insider Trading - Stock Titan
Eton Pharmaceuticals (NASDAQ:ETON) Shares Down 6%Should You Sell? - MarketBeat
Eton Pharmaceuticals Inc (ETON) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.67%
2.13%
자본화:
|
볼륨(24시간):